Cassava Sciences Inc.
416 Browning Way
South San Francisco
California
94080
United States
Tel: 650-624-8200
Fax: 650-624-8222
Website: http://www.paintrials.com/
278 articles about Cassava Sciences Inc.
-
Cassava Sciences Reports Third Quarter 2021 Financial Results
11/10/2021
Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced financial results for the third quarter ended September 30, 2021.
-
Review by Journal of Neuroscience Shows No Evidence of Data Manipulation in Technical Paper Foundational to Cassava Sciences’ Lead Drug CandidateIt states, “No evidence of data manipulation was found for Western blot data.”
11/4/2021
Cassava Sciences, Inc. has been informed by the Journal of Neuroscience that there is no evidence of data manipulation in an article it published in July 2012 describing a new approach to treating Alzheimer's disease.
-
Cassava Sciences Initiates a Phase 3 Efficacy Trial of Simufilam for the Treatment of Patients with Alzheimer’s Disease
10/6/2021
Cassava Sciences, Inc. (Nasdaq: SAVA), a biotechnology company focused on Alzheimer’s disease, announced today it has initiated an initial Phase 3 efficacy study of simufilam, the Company’s investigational drug for patients with Alzheimer’s disease.
-
Cassava Sciences announced top-line results Wednesday from a 12-month interim analysis of its Alzheimer’s drug candidate simufilam.
-
Cassava Sciences Announces Top-line Results of 12-month Interim Analysis from Open-label Study Evaluating Simufilam in Alzheimer’s Disease
9/22/2021
Cassava Sciences, Inc. (Nasdaq: SAVA) announced top-line clinical data today from a pre-planned interim analysis of an on-going open-label study with its drug candidate simufilam in patients with mild-to-moderate Alzheimer’s disease.
-
Cassava Sciences to Present at H.C. Wainwright’s 23rd Annual Global Investment Conference
9/9/2021
Cassava Sciences, Inc. announced today that management will present at H.C. Wainwright’s 23rd Annual Global Investment Conference, a virtual event that takes place September 13-15, 2021.
-
UPDATED: Cassava Sciences Responds to Allegations that Data is Manipulated and “Defies Logic”
8/27/2021
The petition was posted on Monday by shareholder rights law firm Labaton Sucharow. -
Cassava Sciences Releases Statement Regarding Plasma p-tau Analysis from a Previously Disclosed Phase 2b Clinical Study in Alzheimer’s Patients
8/27/2021
Cassava Sciences, Inc. (Nasdaq: SAVA), a biotechnology company focused on Alzheimer’s disease, today released a statement regarding plasma p-tau analysis from a previously disclosed randomized, controlled Phase 2b clinical study in patients with Alzheimer’s disease.
-
Cassava Sciences Responds to Allegations
8/25/2021
Cassava Sciences, Inc. today issued a response to claims that were posted on-line yesterday after market hours. Cassava Sciences believes the claims made in this post regarding scientific integrity are false and misleading.
-
Cassava Sciences Announces Agreement with FDA on Special Protocol Assessments (SPA) for its Phase 3 Studies of Simufilam for the Treatment of Alzheimer’s DiseasePhase 3 Study Initiation Still Expected Fall 2021
8/24/2021
Cassava Sciences, Inc. announced today that it has reached agreement with the U.S. Food and Drug Administration (FDA) under a Special Protocol Assessment (SPA) for both of its pivotal Phase 3 studies of oral simufilam for the treatment of patients with Alzheimer’s disease.
-
Cassava Sciences Reports Second Quarter 2021 Financial Results- Conference Call Today at 9 a.m. ET -
8/3/2021
Cassava Sciences, Inc. today announced financial results for the second quarter ended June 30, 2021.
-
Cassava Sciences Announces Conference Call for Second Quarter Financial Results- Call-in on Tuesday, August 3rd at 9 a.m. ET -
8/2/2021
Cassava Sciences, Inc. (Nasdaq: SAVA), a biotechnology company focused on Alzheimer’s disease, will release financial results for the period ending June 30, 2021 on Tuesday, August 3, 2021 before the market opens, followed by a conference call.
-
Cassava Sciences Announces Positive Cognition Data With Simufilam in Alzheimer’s Disease
7/29/2021
Cassava Sciences, Inc. (Nasdaq: SAVA) announced positive clinical data today from an interim analysis of an open-label study with simufilam, the Company’s investigational drug for the treatment of Alzheimer’s disease.
-
Cassava Sciences Announces Positive Biomarker Data with Simufilam in Alzheimer’s Disease
7/29/2021
Cassava Sciences, Inc. (Nasdaq: SAVA) today announced positive biomarker data from an open-label study of simufilam, the Company’s investigational drug for the treatment of Alzheimer’s disease.
-
Cassava Sciences Announces Positive Data with SavaDx from a Randomized Controlled Phase 2b Study of Simufilam
7/26/2021
Cassava Sciences, Inc. (Nasdaq: SAVA) today announced positive clinical data with SavaDx, an investigational diagnostic/biomarker to detect Alzheimer’s disease with a simple blood test.
-
Today is the first day of the Alzheimer’s Association International Conference 2021 (AAIC), behind held both virtually and in person in Denver, Colorado. Here’s a look at some of today’s stories.
-
Cassava Sciences to Present New Clinical Dataset at 2021 Alzheimer’s Association International Conference
7/21/2021
Cassava Sciences, Inc. today announced it will present two new clinical datasets for its product candidates at the 2021 Alzheimer’s Association International Conference July 26-30.
-
Cassava Sciences Selects Clinical Research Organization for Phase 3 Clinical Program in Alzheimer’s DiseaseSelection of Premier Research as CRO Marks Significant Milestone Toward Initiation of Phase 3 Program of Simufilam in Alzheimer’s Disease
6/21/2021
Cassava Sciences, Inc. (Nasdaq: SAVA), a biotechnology company focused on Alzheimer’s disease, today announced the selection of Premier Research International as its clinical research organization (CRO) to help conduct the Phase 3 clinical program of simufilam for Alzheimer’s disease.
-
Cassava Sciences Provides Mid-Year Corporate Update, Clinical Development Progress and Announces Guidance on Clinical Data Release
6/21/2021
Cassava Sciences, Inc. today announced a mid-year update that highlights clinical development progress and provides guidance on upcoming data releases for simufilam and SavaDx. Simufilam is Cassava Sciences’ lead drug candidate to treat Alzheimer’s disease; SavaDx is an investigational diagnostic candidate to detect Alzheimer’s with a simple blood test.
-
Cassava Sciences to Present at the Raymond James 2021 Human Health Innovation Conference
6/17/2021
Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced that it has been invited to present at the Raymond James 2021 Human Health Innovation Conference,